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Abstract
Background: Therapeutic antibody development is one of the fastest growing areas of the pharmaceutical industry.
Generating high-quality monoclonal antibodies against a given therapeutic target is very crucial for the success of the drug
development. However, due to immune tolerance, some proteins that are highly conserved between mice and humans are
not very immunogenic in mice, making it difficult to generate antibodies using a conventional approach.
Methodology/Principal Findings: In this report, the impaired immune tolerance of NZB/W mice was exploited to generate
monoclonal antibodies against highly conserved or self-antigens. Using two highly conserved human antigens (MIF and
HMGB1) and one mouse self-antigen (TNF-alpha) as examples, we demonstrate here that multiple clones of high affinity,
highly specific antibodies with desired biological activities can be generated, using the NZB/W mouse as the immunization
host and a T cell-specific tag fused to a recombinant antigen to stimulate the immune system.
Conclusions/Significance: We developed an efficient and universal method for generating surrogate or therapeutic
antibodies against ‘‘difficult antigens’’ to facilitate the development of therapeutic antibodies.
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Introduction
Both in vitro and in vivo approaches are used for monoclonal
antibody development. In vitro approaches, such as phage display
or ribosomal display, select antibody sequences from an
immunoglobulin variable chain cDNA library, while in vivo
approaches use immunized animals as hosts and screen for
monoclonal antibodies with conventional hybridoma techniques.
Since the animal immune system is designed by nature for high
affinity and highly-specific antibody development, the in vivo
approach is obviously more cost effective than the in vitro
approach.
Tolerance – the ability of the immune system to prevent
responses to self antigens – makes it difficult to generate a strong
immune response in mice with a mouse self-antigen or highly
conserved human antigen [1]. Currently, specific knockout mice
are used to overcome the immune tolerance associated with self-
antigens. Generation of knockout mice for every mouse antigen
that we need to raise antibodies for is obviously both costly and
time-consuming. In certain cases when knockout mice are
immune-deficient or die prematurely, it is even more difficult if
not impossible to raise antibodies against those antigens.
Systematic autoimmune diseases, however, indicate the presence
of anergic self-reactive B and T cells in the immune repertoire, and
present opportunities for the loss of tolerance leading to strong
antibody responses against self antigens [2]. High titers of serum
antibodies reacting to self-antigens are found in mouse human
SLE-like models (NZB/W and MRL/lpr mice) without prior
immunization with the corresponding self-antigens [3,4]. In fact,
auto-immune NZB mice have been used successfully to generate
antibodies against carbohydrate determinants in myelin-associated
glycoprotein [5], capsular polysaccharides in group B Neisseria
meningitides [6], and glycosphingolipid asialo-GM1 [7]. Recently,
monoclonal antibodies against the highly conserved bovine
recombinant prion protein have also been generated using
NZB/W mice [8]. However, due to the multi-specificity and low
affinity of auto-antibodies from NZB/W mice, there are still
doubts whether therapeutic antibodies with high affinity and high
specificity, as well as the desired biological activities, can be
obtained from this type of mouse.
In this report, three pro-inflammatory cytokines, TNF-alpha,
MIF and HMGB1 were used as test antigens in our efforts
to exploit a new method to generate antibodies against highly
conserved antigens. All three have been implicated as good
drug targets for inflammation related diseases [9,10,11]. Human
MIF and HMGB1 are representatives of highly conserved pro-
teins and mouse TNF-alpha represents mouse self antigens.
Our results demonstrate that monoclonal antibodies with high
affinity and high specificity can be generated from NZB/W mice
and that some of these antibodies possess neutralizing activity
which is very useful in target validation and therapeutic antibody
development.
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Ethics Statement
Maintenance of mice and experimental procedures were
approved by the Animal Welfare and Research Ethics Committee
of the Institute of Biophysics, Chinese Academy of Sciences.
Recombinant protein expression
Human MIF and mouse TNF-alpha were cloned into a PET-
24a vector (Novagen) and expressed in Escherichia coli (E.coli). MT-
tagged HMGB1 was cloned into a PET-41d-MT vector (a
pET41a variant with the GST coding sequence deleted and a
sequence coding for the DQVHFQPLPPAVVKLSDAL polypep-
tide added to the C-terminus). The proteins were expressed in
E.coli strain BL21(DE3) and purified by affinity chromatography
using Ni-NTA His bind resins (Novagen) according to the
manufacturer’s instructions. All GST-tagged HMGB1 constructs
were cloned into the expression vector pET41a, expressed in E.coli
strain BL21(DE3) and purified with GSTNBind
TM Purification Kits
(Novagen) according to the manufacturer’s protocol.
Immunization and hybridoma selection
Female BALB/c and NZB/W mice (12 weeks old) were injected
subcutaneously with 50 mg of purified recombinant protein
emulsified in complete Freund’s adjuvant. Two additional
injections of 50 mg of antigen emulsified in incomplete Freund’s
adjuvant were followed at bi-weekly intervals starting four weeks
after the first immunization. Ten days after the second boost, the
serum antibody titer was tested using ELISA. Two weeks after the
second boost, the mice were given a final booster injection
intraperitoneally with 50 mg protein. Three days after the last
injection, spleen cells from the immunized mice were fused with
myeloma Sp2/0 cells [12]. ELISA was employed for screening
antigen-specific monoclonal antibodies.
ELISA
Antigen (10 mg/ml) was coated on microtiter plates overnight at
4uC. 100 ml of antisera diluted in PBST was added and plates were
incubated for 2 hours at room temperature (RT). After washing, a
1:1000 dilution of HRP-conjugated goat anti-mouse Ig polyclonal
antibody (R&D Systems) was added for 1 hour at RT. 100 ml
substrate (TMB system) was added and plates were read at
450 nm. For dissociated constant (Kd) measurement, purified
monoclonal antibodies were used as the primary antibody with a
two-fold serial titration. The Kd was determined as the antibody
concentration that can achieve 50% of the maximum ELISA
reading. For antibody isotype characterization, HRP-conjugated
rat anti-mouse IgG1, IgG2a or IgG2b monoclonal antibodies (BD
Pharmingen) were used as the secondary antibody instead of the
polyclonal antibody described above.
Yeast display
Primers were designed for cloning the cDNA encoding human
MIF. PCR-amplified fragments were gel-purified using a gel-
extraction kit (Tiangen), and then transformed into EBY100 cells
along with a Not I/EcoR I-digested-pYDS vector, according to a
LiAC-based protocol as previously described [13]. Yeast clones
expressing human MIF were cultured in SD-CAA media (2% (w/
v) dextrose, 0.67% (w/v) yeast nitrogen base, and 1% (w/v)
Casamino acids) for 36 hours at 30uC.
Approximately 4610
8 yeast cells were pelleted by centrifugation
and transferred to SG-CAA (2% (w/v) galactose) media to induce
protein expression and then cultured for 36 hours at 20uC.
Induced yeast cells were pelleted and washed in PBS with 1% (w/
v) BSA. Cells were incubated with the indicated concentrations of
biotinylated or non-biotinylated anti-MIF antibodies for half an
hour at room temperature. Cells were then washed twice with
PBS-BSA and incubated with FITC-labeled goat anti-mouse Ig for
30 minutes. Finally, cells were washed twice with PBS-BSA and
analyzed by flow cytometry.
In vitro functional assays
Raw264.7 cells were treated with 3 mg/ml recombinant human
MIF with or without anti-MIF antibody 10C3(titrated serially with
a starting concentration of 100 mg/ml). After 16 hours, the
supernatant was collected and nitric oxide concentration was
measured with the Griess reagent system (Promega) according to
the manufacturer’s protocol.
8610
5 Raw264.7 cells were stimulated with 1 mg/ml HMGB1
for 8 hours, with or without 50 mg/ml anti-HMGB1 antibodies.
Total mRNA was extracted with Trizol (Invitrogen) according to
the manufacturer’s protocol. 2 mg of total RNA was used in a
25 ml final volume oligo dT primed reverse transcription reaction
using a MLV RT kit (Promega) according to the manufacturer’s
protocol. Target genes were assayed in 20 ml PCR reactions
containing 10 ml SYBR Green PCR Mix (Qiagen), 5pmol sense/
anti-sense primers and 2 ml of the RT reaction. 40 cycles of
quantitative PCR was performed in a Rotor-Gene 6000 real time
PCR machine (Corbett). Primers used in the IL-6 mRNA RT-
PCR assay were as follows:
Mouse IL-6 primers for real-time PCR assay:
Sense: 59-AACGATGATGCACTTGCAGA
Anti-sense: 59-GAGCATTGGAAATTGGGGTA




6–8 week-old C57BL/6 mice, weighing between 18 and 20 g,
were randomly divided into groups. Mice were injected intraper-
itoneally with indicated doses of Lipopolysaccharides (LPS) (from
E. coli strain 0111:B4 , Sigma L2630) or LPS plus indicated doses
of monoclonal antibodies. The number of surviving mice was
recorded every six hours.
Statistical Analysis
Data were expressed as the means6SEM. Differences were
analyzed using Dunnett’s multiple comparison tests. p values
,0.05 were regarded as significant. Statistical significance of
survival rate was determined using log-rank (Mantel-Cox) test.
Results
Macrophage migration inhibitory factor (MIF) is an important
mediator of inflammatory responses and a drug target for sepsis
and auto-immune diseases [10,14]. The human and mouse MIF
proteins share 89% sequence identity. When NZB/W and BALB/
C mice were immunized with a recombinant human MIF protein,
only NZB/W mice generated good serum antibody titers (Fig. 1A).
From the immunized NZB/W mice, 6 hybridoma clones (out of
136 clones screened) secreting antibodies specific to human MIF
were obtained from NZB/W mice. Three of these, 4E10 (IgG2a),
10C3 (IgG2b) and 2A12 (IgG2b), are high-affinity antibody clones
with dissociation constants (Kds) of 2.5 nM, 1.3 nM and 0.1 nM,
respectively (measured by ELISA). In a competition assay, 10C3
and 4E10 did not compete with 2A12, while 4E10 partially
competed with 10C3, suggesting that these three clones bind to
different epitopes on MIF (Fig. 1B). Of the three clones, 10C3
Antibody Development
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macrophage cell line Raw264.7 (Fig. 1C). Furthermore, 10C3
showed in vivo activity when it rescued LPS-induced lethality in a
mouse sepsis model (Fig. 1D).
HMGB1 is a proven therapeutic target in experimental models
of ischemia, acute respiratory distress syndrome, rheumatoid
arthritis, sepsis, and cancer [9,15]. Due to the fact that the human
and mouse HMGB1 proteins are highly conserved (98% identity)
and that HMGB1-deficient mice die shortly after birth, it is hard
to develop monoclonal antibodies against HMGB1. In this study,
neither wild type nor NZB/W mice developed sufficient serum
antibody titer when immunized with GST-tagged HMGB1
protein. We introduced a universal T cell epitope from a
Mycobacterium tuberculosis antigen [16] into the C-terminus of
HMGB1 and the resulting recombinant protein was used as an
antigen for immunization. The T cell epitope greatly enhanced the
immune response of NZB/W mice to HMGB1 (Fig. 2A). Out of
328 hybridoma clones screened, 17 hybridoma clones that secrete
monoclonal antibodies specific for HMGB1 were identified. Four
of these were high affinity clones, with Kds ranging from 0.5 nM
to 10 nM (measured by ELISA). Two clones bound to the
HMGB1 box A, the other two could only bind to the box A+B,
failing to recognize the box A or box B (Fig. 2B). The binding
specificities of clone 3B1 and 3E8 were further confirmed by
western blot (Fig. 2C, left panel). When whole cell lysates were
used, antibodies from clones 8C5, 3E8 and 3B1 specifically
recognized the endogenous HMGB1in Hela cell lysates (Fig. 2C,
right panel). Antibodies from the three clones also blocked
HMGB1-induced IL-6 mRNA up-regulation in Raw264.7 cells
(Fig. 2D), making these antibodies good candidates for therapeutic
antibodies. In a LPS-induced sepsis model, one of the anti-
HMGB1 clones, 3E8, was tested for in vivo-neutralizing activity.
3E8 protected mice effectively from lethal doses of LPS treatment
(Fig. 2E). 3B1, a box A specific clone, had similar effects in
protecting mice from LPS induced sepsis (data not shown).
Generation of reagent antibodies suitable for in vivo use is
essential in the target validation phase of antibody drug discovery
projects. Rabbit polyclonal or even rat monoclonal antibodies will
trigger an immune response in mice, and can render the antibody
ineffective as early as the second week of treatment. In contrast,
antibodies like mouse anti-mouse TNF-alpha are expected to
avoid host responses and are desirable for efficacy assessments in
mouse disease models and early safety studies. We immunized
NZB/W mice with recombinant mouse TNF-alpha and success-
fully generated 20 hybridoma clones (out of 748 clones screened)
secreting antibodies against mouse TNF-alpha. One antibody
clone bound to mouse TNF-alpha with a high affinity
(Kd=1.4 nM, measured by Surface Plasmon Resonance on a
Biacore3000, Fig. 3A), and good specificity (the epitope mapped to
amino acids 19–40 of the TNF-alpha mature chain, data not
Figure. 1 Generation of high affinity, biologically active anti-MIF antibodies from NZB/W mice. (A) Use of NZB/W mice to break
immune tolerance.NZB/W or BALB/C mice were immunized with His tagged MIF protein. Serum titers were measured by ELISA using GST-MIF
coated plates. Serum titer was defined as the highest dilution of serum at which the A450 ratio (A450 of sample/A450 of negative serum) was greater
than 2.0. (B) Competition assays between three anti-MIF clones, 10C3, 2A12 and 4E10. Human MIF was displayed on the surface of yeast
cells. Yeast cells were incubated with 10 nM of biotin-labeled antibodies, with or without 100 nM of non-biotinylated antibodies as competitors.
Streptavidin-PE was used for secondary labeling. (C) 10C3 inhibits MIF-induced nitric oxide secretion in a macrophage cell line. Raw264.7
cells were stimulated with recombinant MIF (3 mg/ml) and increasing concentrations of anti-MIF antibody 10C3 for 16 hours. Nitric oxide
concentration in the supernatant was detected using the Griess assay. (D) 10C3 protects mice from LPS-induced sepsis. 8 week C57BL/6 female
mice, 10 mice/group, were injected intraperitoneally with 22.5 mg/kg LPS, along with anti-MIF antibody 10C3 or isotype control antibodies (5 mg/
kg). The number of surviving mice was recorded every six hours.
doi:10.1371/journal.pone.0006087.g001
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HMGB1 further increased immune response in NZB/W mice. NZB/W mice were immunized with GST-HMGB1 or HMGB1-MT. Serum titers were
measured by ELISA using HMGB1-His-coated plates. Serum titer was defined as the highest dilution of serum at which the A450 ratio (A450 of
sample/A450 of negative serum) was greater than 2.0. (B) Binding affinity and specificity of anti-HMGB1 antibodies.Antibody binding affinity
was measured by ELISA using HMGB1-His-coated plates and the Kd of each antibody is indicated in the figure. Antibody specificity was measured by
ELISA using the GST-HMGB1 Box (A), GST-HMGB1 Box (B) or GST-HMGB1 Box (A+B) as antigens. (C) Binding specificity of anti-HMGB-1
antibodies. Left panel: 0.3 mg of purified recombinant proteins (A+B:HMGB1-MT, A: GST-boxA, B:GST-boxB) were loaded and separated by
electrophoresis on 10% SDS-PAGE gels. Western blots were carried out with 1% dry milk as the blocking buffer and 2 mg/ml purified antibodies as the
primary antibody. The blots were then labeled with goat anti-mouse Ig-HRP and ECL substrate. 3 mg of purified recombinant proteins were separated
by electrophoresis and stained with Coomassie Brilliant Blue for loading control. Right panel: 1610
7 Hela cells were lysed in 1 ml cell lysis buffer and
mixed with 56SDS sample buffer. 20 ml each of the above samples was separated by electrophoresis on 10% SDS-PAGE gels. Western blots were
carried out with 5% BSA as the blocking buffer and 1 mg/ml biotinylated antibodies as the primary antibody. The blots were then labeled with
streptavidin-HRP and ECL substrate. (D) anti-HMGB1 antibodies blocked HMGB1-induced IL-6 up-regulation. Raw264.7 cells were
stimulated with 1 mg/ml HMGB1 for 8 hours, with or without 50 mg/ml of the antibodies indicated. Total mRNA was extracted with Trizol, and IL-6
mRNA levels were measured by real-time RT-PCR. Data are expressed as the means6SEM (n=3). ** indicating p,0.01 when compared to samples
treated with HMGB1 only. (E) Anti-HMGB1 mAb 3E8 protects mice from LPS-induced sepsis. 8 week-old C57BL/6 female mice, 8 mice/group,
were injected intraperitoneally with 25 mg/kg LPS, along with three different doses of anti-HMGB1 antibody 3E8 or isotype control antibodies. The
number of surviving mice was recorded every six hours.
doi:10.1371/journal.pone.0006087.g002
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blocking TNF-alpha’s cytotoxic effect on L929 cells (Fig. 3B). It
also showed good in vivo activity in the LPS-induced sepsis model
(Fig. 3C).
Discussion
Our work has demonstrated that immunization of NZB/W
mice can be used as an effective and universal method to develop
antibodies against self and highly conserved antigens.
The NZB/W mouse strain spontaneously develops antibodies
against nucleic acids and self-nuclear proteins at 5–6 months of
age. Using standard immunization protocols, we were able to
induce strong antibody responses in this strain against highly
conserved human antigen MIF or mouse self-antigen TNF-alpha
before the onset of auto-immune disease. This is consistent with
the notion that B cell tolerance is generally defective in NZB/W
mice [17]. However, previous work has demonstrated that self-
reactive T-cell cells assisting autoantibody production in NZB/W
mice do not result from a generalized defect in T-cell tolerance,
and that thymic and peripheral tolerance to most self-antigens are
intact in NZB/W mice [18]. This could explain the weak antibody
response observed here against HMGB1, a nuclear protein
expressed at high level in all cells. To by-pass this obstacle, we
introduced a strong T-cell epitope to the C terminus of
recombinant HMGB1 protein. This T cell stimulatory epitope is
from the 38-kDa lipoprotein of the Mycobacterium tuberculosis.
Previous studies showed that this peptide can stimulate T cell
proliferation in mice of H-2b, H-2d, and H-2k haplotypes [19].
Unlike regular fusion partners such as KLH, BSA or GST, this
epitope does not elicit B cell response on its own, avoiding the
disadvantages of autoreactive B cells in competing for T cell help
[16]. Our data demonstrated that tagging the antigen with a T
cell-specific epitope can further boost the immune response, and
this response is stronger than that induced by a GST-HMGB1
fusion protein.
The NZB/W mouse strain has also been used to develop
antibodies against bovine prion protein (PrP) [8]. Multiple
hybridoma clones which secreted antibodies that bound specifi-
cally to different epitopes of PrP were isolated from NZB/W mice
Figure. 3 Characterization of anti-TNF-alpha antibody. (A) Binding affinity of anti-mouse-TNF-alpha antibody. The equilibrium
constant of anti-mTNF-alpha antibody 9C6 was measured by Surface Plasmon Resonance (SPR) using a CM5 sensor chip in a BIACORE3000 at 25uC.
Recombinant mouse-TNF-alpha was captured in the flow cell. Running buffer and different concentrations of anti-mTNFa mAb 9C6 (0.64, 1.28, 2.56,
5.12, 10.24, and 20.48 mM diluted in running buffer) were applied to the antigen-containing flow cell for 3 min at a flow rate of 30 ml/min. The Kd of
9C6 was calculated as 1.4 nM. (B) Anti-mTNF-alpha mAb 9C6 neutralizes TNF-alpha-induced cytotoxicity in L929 cells. 3.5610
5 L929 cells
were treated with 1 mg/ml actinomycin D and 3 ng/ml mouse TNF-alpha for 15 hours. Different dilutions of anti-mTNFa mAb 9C6 (with a starting
concentration of 18 mg/ml) were added to the assay. Cell death was measured by the MTT assay (Thiazolyl Blue Tetrazolium Bromide staining, read at
570 nm) [20]. (C) Anti-TNF-a mAb 9C6 protects mice from LPS-induced sepsis. 8 week-old C57BL/6 female mice, 8 mice/group, were injected
intraperitoneally with 25 mg/kg LPS, along with 2.5 mg/kg anti-TNF-a mAb 9C6 or isotype control antibody. The number of surviving mice was
recorded every six hours.
doi:10.1371/journal.pone.0006087.g003
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affinity of these PrP-specific antibodies was not reported [8]. In
our case when cytokines with clear therapeutic indications were
chosen as test antigens, the goal was to develop high affinity
antibodies with neutralization ability. We were able to demon-
strate that antibodies generated with our method are mostly within
the 1-10 nM Kd affinity range, sufficiently high for therapeutic
purposes.
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